XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.3

Significant agreements - Novartis Collaboration Agreement - Accounting Analysis (Details) - Novartis $ in Thousands	Mar. 27, 2023 USD ($) item
Significant agreements.
Transaction price	$ 50,000
Two combined performance obligations for the first and second targets comprised of the Novartis Research License and the related research and development services during the research term for the first and second targets
Significant agreements.
Combined performance obligations | item	2
Transaction price	$ 18,008
Two material rights associated with limited substitution rights
Significant agreements.
Number of material rights | item	2
Transaction price	$ 2,466
Two material rights associated with options to progress development candidates incorporating radionuclides
Significant agreements.
Number of material rights | item	2
Transaction price	$ 19,684
Two material rights associated with options to progress development candidates not incorporating radionuclides
Significant agreements.
Number of material rights | item	2
Transaction price	$ 9,842

X

- Definition

The number of combined performance obligations.

+ References

No definition available.

+ Details

Name:	bcyc_NumberOfCombinedPerformanceObligations
Namespace Prefix:	bcyc_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the number of material rights usually associated with an option.

+ References

No definition available.

+ Details

Name:	bcyc_NumberOfMaterialRights
Namespace Prefix:	bcyc_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of allocated determined transaction price under revenue recognition arrangement.

+ References

No definition available.

+ Details

Name:	bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice
Namespace Prefix:	bcyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: